Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.40 |
| ▸ | GLRB | P48167 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634380 | 0.83 | TGFBR1 (0.48) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL13162322 | 0.81 | IRAK4 (0.44) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL29505431 | 0.81 | IRAK4 (0.44) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL31268286 | 0.80 | IRAK4 (0.43) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL2080592 | 0.80 | IRAK4 (0.43) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL5251219 | 0.80 | EGFR (0.57) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL27790484 | 0.79 | TGFBR1 (0.42) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL29992322 | 0.79 | AAK1 (0.48) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL8670718 | 0.79 | FDPS (0.50) | TGFBR1IRAK4GSK3BDYRK1AAAK1 | |
| SCHEMBL17643492 | 0.79 | AAK1 (0.48) | TGFBR1IRAK4GSK3BDYRK1AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | disclosed |
| CN-105899505-B | Pyrazoles for the treatment of autoimmune disorders | 武田药品工业株式会社 | 2018-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | BACE1 2192/4885BACE2 4028/4885TGFBR1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.